162 related articles for article (PubMed ID: 31902551)
1. Association of expression of p53, livin, ERCC1, BRCA1 and PARP1 in epithelial ovarian cancer tissue with drug resistance and prognosis.
Zhang Z; Dou X; Yang H; Jia L; Qin K; Gao X; Yang B; Zhang W; Qin C; Zhang F; Shan B
Pathol Res Pract; 2020 Feb; 216(2):152794. PubMed ID: 31902551
[TBL] [Abstract][Full Text] [Related]
2. [The mRNA expression of BRCA1, ERCC1, TUBB3, PRR13 genes and their relationship with clinical chemosensitivity in primary epithelial ovarian cancer].
Zhao D; Zhang W; Li XG; Wang XB; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):196-200. PubMed ID: 22780973
[TBL] [Abstract][Full Text] [Related]
3. Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma.
Mullane SA; Werner L; Guancial EA; Lis RT; Stack EC; Loda M; Kantoff PW; Choueiri TK; Rosenberg J; Bellmunt J
Clin Genitourin Cancer; 2016 Aug; 14(4):352-9. PubMed ID: 26778300
[TBL] [Abstract][Full Text] [Related]
4. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ
Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869
[TBL] [Abstract][Full Text] [Related]
5. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
6. ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
Mesquita KA; Alabdullah M; Griffin M; Toss MS; Fatah TMAA; Alblihy A; Moseley P; Chan SYT; Rakha EA; Madhusudan S
Gynecol Oncol; 2019 May; 153(2):416-424. PubMed ID: 30797591
[TBL] [Abstract][Full Text] [Related]
7. [The protein expression of ERCC1 and survivin in epithelial ovarian carcinoma and their clinical significance].
Xie C; Yin RT; Li YL; Kang DY; Xu L; Yang KX
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Jan; 42(1):86-9. PubMed ID: 21355309
[TBL] [Abstract][Full Text] [Related]
8. Expression of excision repair cross-complementation group 1, breast cancer susceptibility 1, and β III-tubulin in thymic epithelial tumors.
Kaira K; Serizawa M; Koh Y; Miura S; Kaira R; Abe M; Nakagawa K; Ohde Y; Okumura T; Naito T; Murakami H; Takahashi T; Kondo H; Nakajima T; Endo M; Yamamoto N
J Thorac Oncol; 2011 Mar; 6(3):606-13. PubMed ID: 21289518
[TBL] [Abstract][Full Text] [Related]
9. Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.
Steffensen KD; Smoter M; Waldstrøm M; Grala B; Bodnar L; Stec R; Szczylik C; Jakobsen A
Int J Oncol; 2014 May; 44(5):1736-44. PubMed ID: 24585004
[TBL] [Abstract][Full Text] [Related]
10. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer.
Steffensen KD; Waldstrøm M; Jeppesen U; Brandslund I; Jakobsen A
Int J Gynecol Cancer; 2008; 18(4):702-10. PubMed ID: 17961161
[TBL] [Abstract][Full Text] [Related]
11. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
Steffensen KD; Waldstrøm M; Jakobsen A
Int J Gynecol Cancer; 2009 Jul; 19(5):820-5. PubMed ID: 19574766
[TBL] [Abstract][Full Text] [Related]
12. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
[TBL] [Abstract][Full Text] [Related]
13. Expression and role of the inhibitor of apoptosis protein livin in chemotherapy sensitivity of ovarian carcinoma.
Liu X; Wang A; Gao H; Yuan Z; Jiao Y
Int J Oncol; 2012 Sep; 41(3):1021-8. PubMed ID: 22766624
[TBL] [Abstract][Full Text] [Related]
14. BRCAness profile of sporadic ovarian cancer predicts disease recurrence.
Wysham WZ; Mhawech-Fauceglia P; Li H; Hays L; Syriac S; Skrepnik T; Wright J; Pande N; Hoatlin M; Pejovic T
PLoS One; 2012; 7(1):e30042. PubMed ID: 22253870
[TBL] [Abstract][Full Text] [Related]
15. The diagnostic value of DNA repair gene in breast cancer metastasis.
Yang Y; Li X; Hao L; Jiang D; Wu B; He T; Tang Y
Sci Rep; 2020 Nov; 10(1):19626. PubMed ID: 33184404
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
Kang CH; Jang BG; Kim DW; Chung DH; Kim YT; Jheon S; Sung SW; Kim JH
Lung Cancer; 2010 Jun; 68(3):478-83. PubMed ID: 19683826
[TBL] [Abstract][Full Text] [Related]
17. Significance of ERCC1 and Hormonal Receptor Expression in Ovarian Cancer.
El-Moniem Elrawi DA; El Khodary AI; Nassar HR; Darwish AD; Khorshed EN
J Med Invest; 2020; 67(3.4):391-398. PubMed ID: 33148925
[TBL] [Abstract][Full Text] [Related]
18. ERCC1, PARP-1, and AQP1 as predictive biomarkers in colon cancer patients receiving adjuvant chemotherapy.
Abdelrahman AE; Ibrahim DA; El-Azony A; Alnagar AA; Ibrahim A
Cancer Biomark; 2020; 27(2):251-264. PubMed ID: 31903985
[TBL] [Abstract][Full Text] [Related]
19. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
20. ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer.
Muallem MZ; Braicu I; Nassir M; Richter R; Sehouli J; Arsenic R
Anticancer Res; 2014 Jan; 34(1):393-9. PubMed ID: 24403493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]